Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 7, Issue 2, Pages 122-136
Publisher
SAGE Publications
Online
2015-01-16
DOI
10.1177/1758834014566428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
- (2013) A. Koop et al. BRITISH JOURNAL OF DERMATOLOGY
- BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
- (2013) Miles C. Andrews et al. JOURNAL OF CLINICAL ONCOLOGY
- Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
- (2013) Christopher J. Anker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib-Induced Cardiac Tamponade: A Rare But Potentially Life-Threatening Complication
- (2013) Kathleen M. Mahoney et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management
- (2012) Lisa Zimmer ARCHIVES OF DERMATOLOGY
- Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities
- (2012) R. Sinha et al. BRITISH JOURNAL OF DERMATOLOGY
- Ocular Toxicity of Targeted Therapies
- (2012) Daniel J. Renouf et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
- (2012) Amélie Clémentine Seghers et al. MELANOMA RESEARCH
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started